Literature DB >> 17985407

Disease activity score-28 values differ considerably depending on patient's pain perception and sex.

Burkhard F Leeb1, Pia M Haindl, Adil Maktari, Thomas Nothnagl, Bernhard Rintelen.   

Abstract

OBJECTIVE: To determine if the Disease Activity Index including a 28-joint count (DAS28) is equally applicable for the total population with rheumatoid arthritis (RA).
METHODS: Five hundred fifty-seven outpatients with RA [432 women, 125 men; median age 64 yrs (range 0-85), median disease duration 48 mo (range 2-548)] were enrolled consecutively into this cross-sectional study. DAS28, physician's global assessment of disease activity, patient's assessment of pain on visual analog scale, C-reactive protein (mg/dl), rheumatoid factor (RF), and disease duration were recorded. t-tests were applied for all comparisons of DAS28 values. Linear regression analysis was performed for each confounding factor.
RESULTS: The mean DAS28 in female patients was 3.66 +/- 0.57 SEM, and in males 3.01 +/- 1.12 (p < 0.001). DAS values in patients with early RA (< 37 mo) were significantly higher than in patients with advanced RA (3.62 +/- 0.67 vs 3.37 +/- 0.81, respectively; p < 0.017). Regression analysis revealed a highly significant relationship between DAS28 score and patient's pain rating (r = 0.592, p < 0.0001). Pain exerted the greatest influence on the DAS28 (p < 0.0001), while of the other factors only age (p < 0.008 for females, p < 0.007 for males) was also significantly correlated with the DAS28 values.
CONCLUSION: DAS28 values differ considerably depending primarily on the patient's pain perception and gender and to a lesser degree on patient's age, whereas results for disease duration and RF were inconclusive.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17985407

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  21 in total

1.  Biologic therapy response and drug survival for females compared to males with rheumatoid arthritis: a cohort study.

Authors:  Jeffrey Lee; Randal Mason; Liam Martin; Cheryl Barnabe
Journal:  Rheumatol Int       Date:  2014-03-30       Impact factor: 2.631

2.  Relation of interleukin-6 in rheumatoid arthritis patients to systemic bone loss and structural bone damage.

Authors:  Mona Helmy Abdel Meguid; Yousry Hasan Hamad; Rania Shafek Swilam; Mohamed Samy Barakat
Journal:  Rheumatol Int       Date:  2012-04-25       Impact factor: 2.631

3.  [Austrian expert opinion on the standard for expert assessment of course of illness in patients with chronic polyarthritis (rheumatoid arthritis)].

Authors:  Klaus P Machold; Hans Peter Brezinsek; Burkhard F Leeb; Stephan Pflugbeil; Franz Rainer; Franz Singer; Martin Skoumal; Tanja A Stamm; Manfred Herold
Journal:  Wien Klin Wochenschr       Date:  2008       Impact factor: 1.704

4.  Interchangeability of 28-joint disease activity scores using the erythrocyte sedimentation rate or the C-reactive protein as inflammatory marker.

Authors:  Liseth Siemons; Harald E Vonkeman; Peter M ten Klooster; Piet L C M van Riel; Mart A F J van de Laar
Journal:  Clin Rheumatol       Date:  2014-02-23       Impact factor: 2.980

5.  Effect of daily low dose prednisone, divided or single daily dose, in the treatment of African Americans with early rheumatoid arthritis.

Authors:  Shuling Li; Doyt L Conn; Athan Tiliakos; Gaobin Bao; Kirk A Easley
Journal:  Clin Rheumatol       Date:  2018-01-03       Impact factor: 2.980

6.  Sex differences in response to anti-tumor necrosis factor therapy in early and established rheumatoid arthritis -- results from the DANBIO registry.

Authors:  Damini Jawaheer; Jørn Olsen; Merete Lund Hetland
Journal:  J Rheumatol       Date:  2011-11-15       Impact factor: 4.666

7.  Measuring inflammation in rheumatoid arthritis with a new clinical and ultrasound index: development and initial validation.

Authors:  Juan José de Agustín; Alba Erra; Andrés Ponce; Carmen Moragues; Cesar Díaz-Torné; Delia Reina; Estefanía Moreno; Julio Ramírez; Lourdes Mateo; Manel Pujol Busquets; Patricia Moya; Pilar Santo-Panero; Sergi Ros-Expósito; Javier Narváez; Raimon Sanmartí; Mª Jesús García de Yébenes; Loreto Carmona
Journal:  Rheumatol Int       Date:  2019-08-08       Impact factor: 2.631

8.  Disease progression and treatment responses in a prospective DMARD-naive seropositive early rheumatoid arthritis cohort: does gender matter?

Authors:  Damini Jawaheer; Paul Maranian; Grace Park; Maureen Lahiff; Sogol S Amjadi; Harold E Paulus
Journal:  J Rheumatol       Date:  2010-10-01       Impact factor: 4.666

9.  Patients with active rheumatoid arthritis but only few tender and swollen joints: a subgroup with impaired short term outcome.

Authors:  C Fiehn; S Kessler; W Drexler; H M Lorenz
Journal:  Rheumatol Int       Date:  2008-11-08       Impact factor: 2.631

10.  Women, men, and rheumatoid arthritis: analyses of disease activity, disease characteristics, and treatments in the QUEST-RA study.

Authors:  Tuulikki Sokka; Sergio Toloza; Maurizio Cutolo; Hannu Kautiainen; Heidi Makinen; Feride Gogus; Vlado Skakic; Humeira Badsha; Tõnu Peets; Asta Baranauskaite; Pál Géher; Ilona Ujfalussy; Fotini N Skopouli; Maria Mavrommati; Rieke Alten; Christof Pohl; Jean Sibilia; Andrea Stancati; Fausto Salaffi; Wojciech Romanowski; Danuta Zarowny-Wierzbinska; Dan Henrohn; Barry Bresnihan; Patricia Minnock; Lene Surland Knudsen; Johannes Wg Jacobs; Jaime Calvo-Alen; Juris Lazovskis; Geraldo da Rocha Castelar Pinheiro; Dmitry Karateev; Daina Andersone; Sylejman Rexhepi; Yusuf Yazici; Theodore Pincus
Journal:  Arthritis Res Ther       Date:  2009-01-14       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.